A5072815736- Dementia and Cognitive Impairment Research
- Alzheimer's disease research and treatments
- Statistical Methods in Clinical Trials
- Gene Regulatory Network Analysis
- Neurogenesis and neuroplasticity mechanisms
- Health Systems, Economic Evaluations, Quality of Life
- CRISPR and Genetic Engineering
- Pluripotent Stem Cells Research
- Intensive Care Unit Cognitive Disorders
- Developmental Biology and Gene Regulation
- Cancer-related cognitive impairment studies
- Diet and metabolism studies
- Pharmacological Effects and Toxicity Studies
- Pharmaceutical Economics and Policy
- Amyloidosis: Diagnosis, Treatment, Outcomes
- Nutritional Studies and Diet
- Congenital heart defects research
- Frailty in Older Adults
- Epigenetics and DNA Methylation
- Muscle Physiology and Disorders
- Long-Term Effects of COVID-19
- TGF-β signaling in diseases
- Neurological Disorders and Treatments
- RNA Research and Splicing
- Bone Metabolism and Diseases
Alzheimer's Association
2020-2024
Northwestern University
2014-2017
Yale University
2014
University of Rochester
2014
University of Colorado Anschutz Medical Campus
2014
Medical University of South Carolina
2014
National Institutes of Health
2009-2013
Abstract INTRODUCTION Blood tests have the potential to improve accuracy of Alzheimer's disease (AD) clinical diagnosis, which will enable greater access AD‐specific treatments. This study compared leading commercial blood for amyloid pathology and other AD‐related outcomes. METHODS Plasma samples from Disease Neuroimaging Initiative were assayed with AD C2N Diagnostics, Fujirebio ALZPath, Janssen, Roche Quanterix. Outcomes measures positron emission tomography (PET), tau PET, cortical...
This report details the approach taken to providing a dataset allowing for analyses on performance of recently developed assays amyloid beta (Aβ) peptides in plasma and extent which they improve prediction positivity.
Abstract Novel environmental stimuli, such as running and learning, increase proliferation of adult hippocampal neural stem cells (NSCs) enlarge the population new neurons. However, it remains unclear how increased numbers neurons can be generated in a time frame far shorter than required for proliferating to generate these Here, we show that bone morphogenetic protein (BMP) signaling subgranular zone regulates tempo progenitor cell (NPC) maturation by directing their transition between...
Introduction: Blood tests have the potential to improve accuracy of Alzheimer disease (AD) clinical diagnosis, which will enable greater access AD-specific treatments. This study compared leading commercial blood for amyloid pathology and other AD-related outcomes. Methods: Plasma samples from Alzheimers Disease Neuroimaging Initiative were assayed with AD C2N Diagnostics, Fujirebio ALZPath, Janssen, Roche Quanterix. Outcomes measures positron emission tomography (PET), tau PET, cortical...
Networks of transcription factors (TFs) are thought to determine and maintain the identity cells. Here we systematically repressed each 100 TFs with shRNA carried out global gene expression profiling in mouse embryonic stem (ES) Unexpectedly, only repression a handful significantly affected transcriptomes, which changed two directions/trajectories: one trajectory by either Pou5f1 or Sox2; other Esrrb, Sall4, Nanog, Tcfap4. The data suggest that trajectories change already preconfigured...
Here we report the generation and characterization of 84 mouse ES cell lines with doxycycline-controllable transcription factors (TFs) which, together previous 53 lines, cover 7–10% all TFs encoded in genome. Global gene expression profiles 137 after induction for 48 hrs can associate each TF direction differentiation, regulatory pathways phenotypes. These microarray data provide building blocks a variety future biomedical research applications as community resource.
Abstract Introduction The WHO estimates that 55 million people worldwide have dementia and this number is expected to increase 139 by 2050. Founded in 1980, the Alzheimer’s Association world’s leading voluntary health organization AD/ADRD care, support research. Methods Association‐led funding opportunities awards, conferences other activities beginning with COVID‐19 pandemic were reviewed. Results remains committed funding, convening, implementing research studies accelerate global effort...
Abstract The COVID‐19 pandemic has disproportionately affected more vulnerable populations, including those living with dementia. Over 50 million individuals worldwide are Alzheimer's disease (AD) or other dementia, and it is crucial to continue the fight against condition during global pandemic. Since start of mandated lockdowns in March 2020, charity non‐profit organizations that fund AD related dementia research respond needs community, ensuring momentum continues accelerates. Members...
OBJECTIVES/SPECIFIC AIMS Rett syndrome (RTT) is one of the most prevalent female neurodevelopmental disorders that cause severe mental retardation.Mutations in methyl CpG binding protein 2 (MeCP2) present Xq28 locus are mainly responsible for RTT.Following normal development until 6-18 months, classic RTT patients show symptoms, such as loss language and motor milestone, purposeful hand movement, head growth.Using reprogramming technology, we isolated induced pluripotent stem (iPS) cells...
Abstract Plasma biomarkers for Alzheimer’s disease (AD) are increasingly being used to assist in making an etiological diagnosis cognitively impaired (CI) individuals or identify unimpaired (CU) with AD pathology who may be eligible prevention trials. However, a better understanding of the timing plasma biomarker changes is needed optimize their use clinical and research settings. The aim this study was evaluate change key (Aβ42/Aβ40, p-tau217, p-tau181, GFAP NfL) from six different...
Abstract INTRODUCTION Alzheimer's disease (AD) and related dementias (ADRD) present significant health challenges. Understanding their underlying biology, advancing existing new therapies, enhancing care for patients caregivers are critical priorities. METHODS This article utilizes data from the International Related Dementias Research Portfolio (IADRP) to analyze funding patterns Association over past decade. RESULTS As largest nonprofit funder of AD/ADRD research globally, has committed...
Abstract Background A previous comparative analysis of plasma Aβ42/40 immunoassays and mass spectrometry‐based assays conducted in 2021 found that several had strong performance predicting amyloid PET status (Zicha et al., 2022). In the spirit enabling National Institute on Aging Alzheimer’s Association framework for classifying disease (AD) utilizing measures pathology amyloid, tau, neurodegeneration (ATN), we have added to this a newly developed immunoassay an automated, scalable platform....
Abstract Background The National Institute on Aging and the Alzheimer’s Association framework for classifying disease (AD) utilizes measures of pathology amyloid, tau, neurodegeneration (ATN), that can identify participants clinical trials. Currently, amyloid is determined by costly PET or invasive CSF measurements. When applied to participant selection, these are associated with high screen failure rates contribute costs long duration recruitment AD Recent reports indicate plasma beta (Aβ)...